Cargando…

High Incidence of C797S Mutation in Patients With Long Treatment History of EGFR Tyrosine Kinase Inhibitors Including Osimertinib

INTRODUCTION: Although treatment with osimertinib confers survival benefits in patients with lung cancer with the EGFR T790M mutation, the mechanism of acquired resistance to osimertinib remains poorly understood. We conducted a prospective observational study to identify the mechanism on the basis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Osoegawa, Atsushi, Yamaguchi, Masafumi, Nakamura, Tomomi, Morinaga, Ryotaro, Tanaka, Kentaro, Kashiwabara, Kosuke, Miura, Takashi, Suetsugu, Takayuki, Harada, Taishi, Asoh, Tatsuma, Taguchi, Kenichi, Nabeshima, Kazuki, Kishimoto, Junji, Sakai, Kazuko, Nishio, Kazuto, Sugio, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474195/ https://www.ncbi.nlm.nih.gov/pubmed/34590037 http://dx.doi.org/10.1016/j.jtocrr.2021.100191

Ejemplares similares

Osimertinib as first-line treatment for recurrent lung cancer patients with EGFR mutation
por: Osoegawa, Atsushi, et al.
Publicado: (2023)

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S
por: Lategahn, Jonas, et al.
Publicado: (2019)

Effectiveness of afatinib in an NSCLC patient with EGFR mutation and early progression to osimertinib: a case report
por: Nozaki, Koichiro, et al.
Publicado: (2022)

Effective clinical response of lung adenocarcinoma harboring EGFR 19Del/T790M/in cis-C797S osimertinib to osimertinib and gefitinib combination therapy
por: Wang, Yanyan, et al.
Publicado: (2023)

Histological transformation of lung adenocarcinoma to small cell lung cancer with mutant C797S conferring acquired resistance to osimertinib
por: Ren, Xiaohui, et al.
Publicado: (2020)

Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
por: Zhou, Rengui, et al.
Publicado: (2021)

Determination of Somatic Mutations and Tumor Mutation Burden in Plasma by CAPP-Seq during Afatinib Treatment in NSCLC Patients Resistance to Osimertinib
por: Ishii, Hidenobu, et al.
Publicado: (2020)

Overcoming Resistance to Osimertinib by T790M Loss and C797S Acquisition Using Gefitinib in a Patient With EGFR-Mutant NSCLC: A Case Report
por: Enrico, Diego, et al.
Publicado: (2022)

Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B)
por: Fukuda, Minoru, et al.
Publicado: (2016)

A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L)
por: Wakuda, Kazushige, et al.
Publicado: (2020)

A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L)
por: Wakuda, Kazushige, et al.
Publicado: (2023)

The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung cancer cells
por: Murakami, Yuichi, et al.
Publicado: (2017)

Giant benign intrathoracic schwannoma: a decade-long progression towards fatality
por: Miyawaki, Michiyo, et al.
Publicado: (2023)

The role of comprehensive analysis with circulating tumor DNA in advanced non‐small cell lung cancer patients considered for osimertinib treatment
por: Sueoka‐Aragane, Naoko, et al.
Publicado: (2021)

Possibility of brigatinib‐based therapy, or chemotherapy plus anti‐angiogenic treatment after resistance of osimertinib harboring EGFR T790M‐cis‐C797S mutations in lung adenocarcinoma patients
por: Yang, Yaning, et al.
Publicado: (2021)

Feiyiliu Mixture sensitizes EGFR(Del19/T790M/C797S) mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
por: Shi, Jingjing, et al.
Publicado: (2023)

Edition Eulenburg No. 797, Horn Concerto, : Mi♭ majeur - E♭ major - Es dur KV 495 /

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
por: Zhao, Jing, et al.
Publicado: (2018)

797. Tuberculosis Treatment: Combined Forms vs. Dissociated Forms
por: Trigui, Maroua, et al.
Publicado: (2018)

Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease
por: Ohgushi, Migiwa, et al.
Publicado: (2021)

797 Viral co-infections in hospitalized patients with respiratory tract infections
por: Al-Nakib, Widad, et al.
Publicado: (2014)

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
por: Burckhardt, Peter, et al.
Publicado: (2021)

Correction to Lancet Planet Health 2021; 5: e797–807
Publicado: (2021)

Exploration of resistance mechanisms for epidermal growth factor receptor‐tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next‐generation sequencing
por: Iwama, Eiji, et al.
Publicado: (2018)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

Icotinib plus osimertinib overcome epidermal growth factor receptor 19del/T790 M/C797S/V834L quadruplet resistance mutation in a patient with non-small cell lung cancer
por: Zhu, Chao, et al.
Publicado: (2019)

Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, cis-G796s/cis-C797s by osimertinib, brigatinib, and bevacizumab combination therapy: A case report
por: Chang, Yuan, et al.
Publicado: (2022)

Sorting Out the Risks and Benefits of the #797 Recommended Intrapartum Vancomycin Dosing Approach
por: Farkas, Andras, et al.
Publicado: (2022)

Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4‐ALK fusion gene
por: Kometani, Takuro, et al.
Publicado: (2018)

Tracheal injury from dog bite in a child
por: Miyawaki, Michiyo, et al.
Publicado: (2023)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

TAPO in first‐line osimertinib therapy and continuation of osimertinib
por: Mimura, Chihiro, et al.
Publicado: (2022)

A Prospective Cohort Study Assessing the Relationship between Plasma Levels of Osimertinib and Treatment Efficacy and Safety
por: Fukuhara, Tatsuro, et al.
Publicado: (2023)

Uterine angioleiomyoma with disseminated intravascular coagulation: a case report
por: Sato, Hanako, et al.
Publicado: (2023)

Structural insights into drug development strategy targeting EGFR T790M/C797S
por: Zhu, Su-Jie, et al.
Publicado: (2018)

Overcoming EGFR T790M and C797S resistance with mutant-selective allosteric inhibitors
por: Jia, Yong, et al.
Publicado: (2016)

Growth Suppression in Lung Cancer Cells Harboring EGFR-C797S Mutation by Quercetin
por: Huang, Kuo-Yen, et al.
Publicado: (2021)

797. Infection Prevention and Control Training Needs and Preferences Among Frontline Health Professionals
por: Stream, Sarah, et al.
Publicado: (2021)

P797: METABOLIC PROFILING IN ERCC6L2 AND SHWACHMAN DIAMOND SYNDROME
por: Kaaja, I., et al.
Publicado: (2022)

Edição de Abril de 2022, vol. 118(42), págs. 797-857
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pq8376p8i3e5aj1ua0p5tq5t3t